We examined the effect of insulin and plasma amino acid cohcentrations on leucine kinetics in 15 healthy volunteers (age 22±2 yr) using the euglycemic insulin clamp technique and an infusion of [1-'4Cjleucine. Four different experimental conditions were examined: (a) study one, high insulin with reduced plasma amino acid concentrations; (b) study two, high insulin with maintenance of basal plasma amino acid concentrations; (c) study three, high insulin with elevated plasma amino acid concentrations; and (d) study four, basal insulin with elevated plasma amino acid concentrations. Data were analyzed using both the plasma leucine and alpha-ketoisocaproate (the alphaketoacid of leucine) specific activities.
Introduction
In vitro studies have demonstrated that insulin enhances amino acid uptake (1, 2) and stimulates protein synthesis (3, 4) by muscle. Moreover, many investigators have shown that in-Receivedfor publication II June 1986 and in revisedform 15 April 1987. sulin exerts an antiproteolytic action on both muscle (5) and liver (6) . These in vitro data provide strong evidence that insulin plays an important anabolic role in the physiologic regulation of protein synthesis/degradation and amino acid metabolism. However, similar effects have been difficult to demonstrate in vivo. In type 1 diabetic subjects, insulin withdrawal is associated with a negative nitrogen balance (7) , an increase in the plasma concentrations of the branched chain amino acids (leucine, isoleucine, and valine), and an increase in total leucine flux and leucine oxidation (8, 9) . All of these metabolic disturbances are reversible with appropriate insulin treatment (10) . In normal subjects, insulin induces a dose-related decrease in leucine flux and a marked decrease in the estimated rate of protein synthesis (1 1, 12) .
The discrepancy between in vivo (1 1, 12) and in vitro (1-4) results may be explained in part by the well known amino acid lowering effect of insulin that occurs in the intact organism (13) . Thus, the resultant hypoaminoacidemia may lead to limitation in substrate availability for protein synthesis and antagonize a protein anabolic effect of insulin in vivo. This hypothesis is supported by the studies from O'Keefe et al. (14) in postsurgical patients and from Nissen et al. (15) in dogs. These investigators demonstrated an anabolic effect on protein metabolism only in the presence of increased plasma insulin concentration and maintainance of plasma amino acid concentrations. The present study was undertaken to examine the separate effects of insulin and plasma amino acid concentrations on leucine metabolism in normal subjects.
Methods
Subjects. 15 healthy volunteers participated in the four experimental protocols. All subjects were within 20% of their ideal body weight (mean±SEM = 100±2%) (based upon the midpoint for medium frame individuals from the Metropolitan Life Insurance Tables, 1959) . Their weight and height were 72±3 kg and 178±4 cm, respectively. Subjects ranged in age from 18 to 39 yr (mean = 22±2 yr). There were 10 males and 5 females. No subject had any history of renal, cardiovascular, or endocrine disease and all were consuming a weight-maintaining diet containing at least 250 g of carbohydrate/d and between 80 to 120 g of protein/d for at least 3 d before each study;
The purpose and potential risks of the study were explained to all subjects, and their voluntary written consent was obtained before their participation. The study protocol was reviewed and approved by the Human Investigation Committee of the Yale University School of Medicine.
Experimental protocol (Fig. 1 In each study protocol a primed-continuous infusion of [ multiplying the '4CO2 specific activity by the total CO2 production rate determined as described below.
At the end of the 3-h basal period one of the following study protocols was performed.
Study one, insulin clamp. Eight subjects were studied in this protocol. After the 180-min equilibration period, a prime-continuous infusion of crystalline porcine insulin (Eli Lilly & Co., Indianapolis, IN) was administered at the rate of 40 mU/m2 * min for an additional 180 min to achieve and maintain an increment in plasma insulin concentration of 80 MU/ml. The plasma glucose was maintained constant at the basal level by determination of the plasma glucose concentration at 5-min intervals and periodic adjustment of a 20% glucose infusion as previously described (16 Study three, insulin clamp plus increased plasma amino acid concentration. In seven subjects who participated in study one, the insulin clamp was performed as described above but the rate of amino acid infusion was increased to either 0.02 ml/kg min (n = 3) or 0.033 ml/kg-min (n = 4) (leucine infusion rates of 1.11 Respiratory exchange measurement. In all studies, total CO2 production rate was performed as previously described (17) . Briefly, a plastic ventilated hood was placed over the head of the subject and made air tight around the neck. A slight negative pressure was maintained in the hood to avoid loss of expired air. Ventilation was measured by means of a dry gas meter. The carbon dioxide content of expired air was continuously measured by an infrared carbon dioxide analyzer (model CD-3A; Applied Electrochemistry Inc., Sunnyvale, CA).
Analytical determinations. Plasma leucine specific activity was determined in Dr. DeFronzo's laboratory in all 27 studies using an amino acid analyzer (D500; Dionex Corp., Sunnyvale, CA). To precipitate plasma proteins, 2.5 ml of 10% sulfosalicylic acid was added to 2.5 ml of plasma and a l-ml aliquot of the supernatant was analyzed in duplicate for amino acid concentration. 1 ml of the remaining supernatant was placed in duplicate on a cation exchange resin column (Dowex 5OG; Bio-Rad Laboratories, Richmond, CA) and the free amino acid fraction was eluted with 4 N NH40H, dehydrated, and reconstituted in water (14) . 10 ml of hydrofluor scintillation fluid was added to each vial and '4C radioactivity was measured in a scintillation counter. The recovery of ["4C]leucine added to plasma was 98±2%.
The interassay and intraassay variations for the determination of ['4C]leucine specific activity were 4±2 and 5±2%, respectively. More than 98% of the radioactivity collected in the amino acid fraction was in the leucine peak after separation by ion exchange chromatography.
Recent studies by Matthews et al. (18) and Schwenk et al. (19) have indicated that the total leucine carbon flux and the rate of leucine oxidation may be underestimated if calculations are performed using the plasma leucine specific activity. Because oxidation of leucine takes place only after transamination to alpha-ketoisocaproate (alpha-KIC)'
and since intracellular alpha-KIC and leucine are in rapid equilibration, some investigators have suggested that the plasma alpha-KIC specific activity may provide a better estimate of the intracellular precursor pool when calculating rates of leucine oxidation and leucine flux (18) (19) (20) . In 20 subjects (5 in study one, 5 in study two, 4 in study three, 6 in study four) sufficient plasma was available to measure the plasma alpha-KIC, as well as leucine specific activity in simultaneously drawn samples in the laboratory of Dr. Haymond (21, 22 (27) . An estimate of the rate of leucine incorporation into protein (S) can be calculated as follows: S = Q -C.
An estimate of the rate of leucine release into the plasma space from endogenous protein (B) can be calculated as follows: B = Q -I.
When the subjects are in the postabsorptive state, the leucine intake (I) equals zero and B = Q. When amino acids are being infused intravenously (i.e., as in study protocols 2-4), the rate ofleucine infusion (I) must be subtracted from the total leucine flux (Q) in order to calculate the rate ofendogenous leucine release from protein. The rate ofexogenous leucine infusion was calculated as the product of the infusate leucine concentration in micromoles per milliliter and the infusion rate in milliliters per minute. Finally, the net balance of leucine flux into or out of protein was calculated as the difference between the nonoxidative leucine disposal (an estimate of protein synthesis) and the endogenous rate of leucine appearance (an estimate of protein degradation).
The above described model assumes that the plasma leucine specific activity accurately reflects the intracellular specific activity of leucine. Recent data, however, suggest that the plasma specific activity of the transaminated product of leucine, alpha-ketoisocaproate (KIC) may provide a better indicator ofthe specific activity in the intracellular mixing pool (18) (19) (20) . Therefore, estimates of leucine kinetics were also carried out using estimates of the plasma ['4C]KIC specific activity. Thus, all of the calculations of leucine turnover were repeated using the above equations but with substitution of the "estimated" plasma ["4C]KIC specific activity for the plasma leucine specific activity. In this study (see Table II ) the ratio of KIC to leucine specific activity was quite constant during each of the four experimental protocols (0.68±0.02) and was identical to the ratio observed in the basal state (0.68±0.02). In additional studies performed in insulin-dependent diabetic subjects (28), we also have shown that neither insulin nor amino acid infusion alters the ratio of KIC/leucine specific activity.
Similar results have been reported by Tessari et al. ( 11) and Fukagawa et al. (12) . Ideally, one should use the intracellular leucyl t-RNA specific activity when calculating total leucine flux. Unfortunately, however, the specific activity of this precursor pool can not be determined in man. Six studies (29) (30) (31) (32) (33) (34) from three different laboratories have examined the intracellular leucyl t-RNA pool in vitro and in vivo. Five of six have reported the t-RNA specific activity to be quite similar to the plasma leucine specific activity (29, (31) (32) (33) (34) , whereas one found a somewhat lower specific activity (30) . Thus, at present, it can not be known with certainty what is the actual precursor specific activity to be used when calculating rates ofleucine turnover. Taken in this context, the leucine flux rates determined from the plasma leucine and KIC specific activities might better be viewed as providing minimum and maximum estimates, respectively. Of particular importance with respect to the present work, none of the major conclusions are altered whether one uses the plasma leucine or estimated KIC specific activities.
Glucose metabolism. During the euglycemic insulin clamp studies, the glucose infusion rate was averaged over the final 60-to 180-min time period. Under similar conditions of hyperinsulinemia we have previously shown that endogenous glucose production is suppressed > 90-95% (35). Therefore, the total amount of glucose taken up by the entire body closely approximates the exogenous glucose infusion rate required to maintain euglycemia. Steady state plasma glucose and insulin concentrations represent the mean of values taken during the 60-180-min time period.
Statistical analysis. All values are expressed as the mean±SEM.
Comparisons between the basal and insulin stimulated state within a group were performed using the t test for paired data. Intergroup comparisons were performed by analysis of variance.
Results
Plasma amino acid concentrations and plasma leucine specificity activity. During study one we observed a consistent decrease in most plasma amino acid concentrations with the notable exception of alanine (Table I, Fig. 2 ). The total plasma amino acid concentration decreased from 1913±58 to 1427±50 ,gmol/liter (P < 0.001). Branched chain amino acids (BCAA) declined from 406±15 to 217±4 umol/liter (P < 0.001); in particular, plasma leucine fell from 127±5 to 57±3 gmol/liter (P < 0.001). A steady state plateau concentration was reached for all BCAA during the last hour of study. Between 120 and 180 min of insulin infusion the plasma concentrations of leucine (59±2 vs. 56±3 Mmol/liter), isoleucine (25±3 vs. 21±2 ,umol/liter), and valine (140±4 vs. 135±4
,gmol/liter) were not significantly different (P > 0.50) (Fig. 2) .
In study two both total and branched chain amino acid concentrations did not change significantly from their basal values (1901±117 vs. 2368±123 and 409±27 vs. 419±22 Amol/liter, respectively). Specifically, the plasma leucine concentration was maintained close to the basal level (127±3 and 114±4 Amol/liter at 0 and 180 min, respectively) (Fig. 2) . A steady state plateau for all BCAA was reached during the last hour of study.
In study three a significant increase in both total and branched chain amino acid concentrations (1,972±84 vs. 3,504±304 and 417±18 vs. 835±34 ,umol/liter, respectively) was observed. Plasma leucine concentration increased twofold, from a baseline value of 122±4 to 214±25 ,umol/liter at 180 min (P < 0.001, Fig. 2) .
In study four the total plasma amino acid concentration increased from 2127±103 to 4536±238 smol/liter (P < 0.001) and the branched chain amino acid concentration from 434±21 to 970±21 ,umol/liter (P < 0.001). Basal plasma leucine concentration was 122±6 ,umol/liter and increased to 284±10 ,mol/liter during the amino acid infusion period (P < 0.001, Fig. 2 ).
During the last hour of the basal equilibration period and during the 120-180-min of the experimental period a steady state plateau of plasma leucine specific activity (counts per minute per nanomole and disintegrations per minute per nanomole carried out in Dr. DeFronzo's and Dr. Haymond's laboratories, respectively) was reached in all four study protocols (Table I and Fig. 2 ).
Plasma alpha-KIC concentration and specific activity. In five patients in study one, five in study two, four in study three, and six in study four plasma alpha-KMC concentrations and specific activity were determined in the laboratory of Dr. Haymond (19) . Basal plasma alpha-KIC concentration was similar in all study protocols (38±5, 34±3, 35±3, and 29±4 Amol/ liter, respectively). In studies one and two they declined to 18±3 and 21±2 14 mol/1iter, respectively, whereas during study three they did not change (32±3 ,umol/liter) and increased slightly (37±3 ,umol/liter) during study four. During the last hour of the equilibration period and during the 120-1 80-min period of the experimental period, the alpha-KIC specific activity (counts per minute per micromole) remained constant in all four study protocols. During the basal equilibration period (120 to 180 min) the ratio of ['4C]KIC specific activity/['4C]leucine specific activity was essentially identical in each of the 20 individuals in whom plasma was available for assay in Dr. Haymond's laboratory and this ratio averaged 0.68±0.02 (Table II) . In each of the four study protocols the ratio of alpha-KIC to leucine specific activity during the last hour (120-180 min) of the experimental period was quite similar to that observed during the postabsorptive state. This observation is consistent with a number of previous publications in which the KIC to leucine specific activity has been shown to remain constant after a number of experimental maneuvers, including insulin infusion (1 1, 12) , protein feeding (36) , and lipid infusion (37) .
For comparison of data for the entire study population (i.e., all 27 subjects), plasma KIC specific activity (counts per minute per millimole) was estimated for each individual by multiplying the leucine specific activity determined in Dr. DeFronzo's laboratory by the mean KIC/leucine specific activity ratio determined in Dr. Haymond's laboratory for each of the four groups (Table II) Table III for each ofthe four experimental groups. As can be seen, the changes in leucine specific activity determined in the laboratories of Drs. DeFronzo and Haymond agreed quite well with one minor exception. In study two the plasma leucine specific activity determined in Dr. DeFronzo's laboratory showed no change, whereas it decreased slightly when determined in Dr. Haymond's laboratory. At present, we have no explanation for this small difference in measured leucine specific activity. It should be noted, however, that while this difference may quantitatively alter the absolute rates of leucine turnover calculated in study two, it does not affect the qualitative changes that were observed.
Total leucine flux. In the postabsorptive state the leucine turnover rate was similar in all four study protocols and averaged 1.12±0.04 ,tmol/kg. min (Fig. 3) . Under conditions of euglycemic hyperinsulinemia (study one), we observed a 40% decrease in the rate of leucine turnover using the ['4C]leucine specific activity (1.16±0.05 to 0.69±0.03 ,umol/kg min, P < 0.01). A similar decrease was observed using the estimated ['4C]KIC specific activity (1.73±0.08 to 1.08±0.07 ,umol/ kg min, P < 0.001). In study two, with the same degree of hyperinsulinemia but with maintenance of basal plasma amino acid levels, the leucine turnover rate remained unchanged (1.08±0.05 vs. 1.06±0.05 ,mol/kg * min) during the insulin infusion using either the ['4C]leucine specific activity or the estimated ['4C]KIC specific activity (1.58±0.04 vs. 1.54±0.04 ,umol/kg. min). In study three (combined hyperinsulinemia and hyperaminoacidemia) and in study four (basal insulinemia and hyperaminoacidemia), the total leucine turnover rate increased from 1.08±0.04 to 1.80±0.09 and from 1.10±0.05 to 1.74±0.09 ,umol/kg min, respectively, using the ['4C]leucine specific activity (P < 0.001 vs. basal and P < 0.001 vs. both studies one and two; Fig. 3 Endogenous leucine flux. In study one amin not infused (Fig. 4) . Therefore, the endogenous equals the total leucine turnover rate. In the p( state, endogenous leucine flux decreased from 0.69±0.03 ,mol/kg min during the euglycemic i using the [14C]leucine specific activity (or 1.73 tU kg m, using the estimated ['4CJKIC specific acti < 0.001 vs. basal). In studies two through fou amino acid solution was infused to maintain o plasma amino acid concentrations. Therefore, the leucine flux was calculated as the difference betw leucine flux and the leucine infusion rate. In study nous leucine flux decreased from 1.08±0.05 ti 5) . When hyperinsulinemia was created but amino acid levels were allowed to drop (study one), leucine oxidation fell _hsuhin significantly to 0.13±0.01 /Amol/kg min (P < 0.01). In contrast, when the same degree of hyperinsulinemia was created nsln+ Basal -Ajno Acidss while maintaining the plasma amino acid concentrations conArnino Acid + SF stant at the basal level (study two), leucine oxidation was en-+ Basal hsulin hanced (0.29±0.02 ,umol/kg min) (P < 0.01). When hyper_nulinoA+bsh aminoacidemia was created, either with hyperinsulinemia (study three) or with euinsulinemia (study four), leucine oxidation was markedly stimulated (both P < 0.01 versus study two) (Fig. 5) (Fig.   6 ). During study one nonoxidative leucine disposal decreased mol/kg. min, by 40% to 0.55±0.03 ,umol/kg min (P < 0.01 vs. basal). In study two, when plasma amino acid levels were maintained at io acids were or slightly below postabsorptive levels, the decline in nonoxileucine flux dative leucine disposal (0.90±0.04 to 0.76±0.03 ttmol/ ostabsorptive kg min) was significantly less than that observed in study one 1.16±0.05 to (P < 0.01). Finally, in both studies three (1.20±0.05 gmol/ nsulin clamp kg * min) and four (1.30±0.08 gmol/kg * min) a significant ino 1.08 ,umol/ crement (both P < 0.01 vs. basal) (both P < 0.01 vs. studies ivity) (both P one and two) in the rate of nonoxidative leucine disposal was ,r a balanced observed (Fig. 6) Net leucine protein balance. In the basal state the net leucine balance with respect to flux into and out of protein was similar in all four study protocols and averaged -0.20±0.02
,umol/kg. min using the ['4C]leucine specific activity (Fig. 7) .
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During study one the net balance increased slightly, but still remained in the negative range, -0. 13±0.12 ,umol/kg* min. In 0.63±0.04 study two, when plasma amino acid concentrations were 0.69±0.07 maintained at the basal postabsorptive level, the net leucine 0.69±0.07 protein balance increased significantly and became positive, 0.68±0.04 0.38±0.04 ,umol/kg min (P < 0.01 vs. study one). Finally, during both studies three and four, the net leucine balance Dr. Haymond's increased further to 0.81±0.04 and 0.66±0.05 ,umol/kg. min, respectively (P < 0.01 vs. studies one and two). Using the ['4C]KIC specific activity, leucine balance in the postabsorptive state was negative, -0.29 ,umol/kg. min. During study one, when only insulin was infused, the net leucine balance remained negative, -0.19 ,umol/kg min. In study two, leucine balance increased from -0.18 to +0.24 ,mol/ kg. min using the estimated ['4C]KIC specific activity. In studies three and four net leucine balance increased from about -0.23 to +0.56±0.03 and +0.48±0.03 ,umol/kg. min, respectively.
Glucose metabolism. During the 60-to 180-min time period, the glucose infusion rates required to maintain euglycemia in the 40 mU/M2 -min insulin clamp studies were 7.6±1.0, 8.1 ± 1.0, and 7.4+ 1.0 mg/kg. min during studies one, two, and three, respectively.
Plasma glucose, insulin, and glucagon concentrations. The fasting plasma glucose concentration was similar in all four study protocols and averaged 86±2 mg/dl. During the euglycemic insulin clamp, the steady state plasma glucose levels (60-180 min) were maintained close to the basal values: 85±2 (study one), 86±2 (study two), 87±2 mg/dl (study three) with coefficients of variation of 4.7±1.0, 4.8± 1.0, and 4.7± 1.0, respectively. In study four the plasma glucose concentration (85±2 mg/dl) remained close to the basal level.
The mean fasting plasma insulin concentration was similar in all four studies and averaged 8±2 AtU/ml. The steady state plasma insulin levels during the 60-180-min time period of the insulin clamp were 76±2, 74±2, and 80±2 ,uU/ml during studies one, two, and three, respectively. In study four the plasma insulin concentration did not change from baseline (10±1 vs. 12±1 ,uU/ml). The mean fasting plasma glucagon concentration was similar in the four studies and averaged 174±14 pg/ml. During the 60-to 180-min time period of the insulin clamp, plasma glucagon either decreased slightly or did not change in the four study protocols, averaging 157±31, 137+12, 184±40, and 216±27 pg/ml, respectively (all P = NS).
Discussion
In this study we have investigated the effects of changes in the plasma insulin and amino acid levels on leucine metabolism in (pmol/kg min) Figure 5 . Effiect of insulin and plasma amino acid levels on leucine oxidation in the basal state and during each of the four study protocols. *P < 0.01 vs. basal; o P < 0.01 vs. study one (insulin); tP < 0.01 vs. study one (insulin) and study two (insulin + basal AA).
normal subjects. In order to evaluate the separate roles of hyperinsulinemia and plasma amino acid concentrations on the regulation of leucine turnover, we employed the euglycemic insulin clamp technique in combination with the infusion of a balanced amino acid solution. This allowed us to independently manipulate the desired variables, i.e., the plasma insulin and amino acid concentrations.
In the first study protocol insulin was infused to create a state of physiologic hyperinsulinemia (70-80 ,tU/ml) and the plasma amino acid concentrations were allowed to drop spontaneously (Table I) which the basal amino acid concentrations were maintained constant, the decline in nonoxidative protein disposal observed during study one was largely prevented. However, a stimulatory effect of combined insulin/amino acid infusion on nonoxidative protein disposal could not be demonstrated in study two. Thus, to the extent that nonoxidative protein disposal provides an index of protein synthesis, we were unable to demonstrate a stimulatory action of hyperinsulinemia on this metabolic parameter.
Despite the above findings, it is well known that protein feeding is associated with repletion of muscle nitrogen (36) . The primary difference between this situation and the experimental conditions in study two is the presence of hyperaminoacidemia following protein loading. Therefore, we repeated the insulin clamp study but doubled the amino acid infusion rate to cause combined hyperaminoacidemia/hyperinsulinemia (study three). Under these experimental conditions nonoxidative leucine disposal was increased above basal rates (P < 0.001) and was significantly greater than when insulin was infused alone (study one; P < 0.01) or with amino acids (study two; P < 0.01) to simply maintain the basal plasma amino acid concentration constant (Fig. 6 ). These results indicate that the stimulation of net protein synthesis in vivo in man is facilitated by the presence of hyperaminoacidemia. This conclusion is consistent with results obtained in study four where hyperaminoacidemia, in the presence of basal insulinemia, significantly enhanced nonoxidative leucine disposal.
The present results also help to elucidate the effects of insulin and plasma amino acid concentration on endogenous leucine flux (Fig. 4) . When amino acids were infused with insulin (studies two and three), the decrease in endogenous leucine appearance was greater than observed in study one (P < 0.01). Furthermore, during study four, when plasma amino acid concentrations were raised while maintaining basal insulinemia, the rate of endogenous leucine appearance declined significantly from baseline (P < 0.01). Taken collectively, these results indicate that the plasma amino acid concentration per se (most likely by maintaining intracellular amino acid levels constant) exerts an inhibitory effect on protein degradation.
Perhaps the most interesting result from the present study is the response of leucine metabolism to hyperaminoacidemia in the presence and absence of hyperinsulinemia. Using the plasma ['4C]leucine specific activity, the combination of hyperinsulinemia and hyperaminoacidemia caused a greater inhibition (P < 0.05) of protein degradation than did hyperaminoacidemia plus maintenance ofbasal plasma insulin concentrations (Fig. 4) . In contrast, the increase in nonoxidative leucine disposal was similar in studies three and four (Fig. 6) . These data would suggest that amino acid availability may play an additive role to insulin in the suppression of endogenous proteolysis, and thus their mechanism of action appears to be different. Such is not the case for estimates of protein synthesis. These conclusions, however, are predicated on the isotope model employed. Recent studies by Schwenk et al. (19) suggest that the total leucine carbon flux and rate of leucine oxidation may be underestimated if calculations are performed using the plasma leucine specific activity during infusion of a leucine tracer. These (19) In summary, it would appear that the primary effect of insulin in man is to inhibit the endogenous leucine flux (protein degradation) while hyperaminoacidemia both stimulates nonoxidative leucine disposal (protein synthesis) while inhibiting the endogenous leucine flux. Both insulin and amino acid infusion augment leucine oxidation.
